Medindia

X

MM2 Group Closes $1.1 Million Sale

Saturday, December 1, 2007 General News J E 4
Advertisement
LIVINGSTON, N.J., Nov. 30 MM2 Group, Inc.(OTC Bulletin Board: MMGP) announced today that its wholly-owned subsidiary,Genotec Nutritionals, Inc., a New York based nutraceutical company whichgenerates its sales from the distribution of its branded products and throughcustom formulations for several large strategic partners, has closed on a verylarge order for high potency odorless fish oil softgels.

The transaction is valued at over $1,100,000, which is to be deliveredover the next 7 months.

Fish oil is known for being rich in unsaturated fatty acids and providesessential Omega-3 fatty acids (EPA and DHA). Fish oil may help reduce orinhibit risk factors involved in cardiovascular disease, cognitive decline,macular degeneration, as well as inflammatory and immune disorders. Omega-3fatty acids also help prevent menopausal symptoms, promotes better circulationand neural development, and lowers cholesterol and triglycerides.

Mark Meller, CEO of MM2 Group, stated, "Genotec is committed to providingcutting edge products to the market in a timely fashion. This order is amongthe largest in the Company's history, and rapidly accelerates our growth plan.We have successfully positioned Genotec to grow into a very large company inthe near future."

About MM2 Group, Inc.

MM2 Group is involved in the acquisition and build-out of dietarysupplement and nutraceutical companies. The company's growth strategy is toacquire firms in this extensive and expanding but highly fragmented segment asit seeks to create substantial value for shareholders. For more information,contact MM2 Group CEO Mark Meller at (732) 290-0019 or by e-mail atmeller@mm2group.net or Jerry Mahoney at jerrym@mm2group.net.

This news release includes forward-looking statements within the meaningof Section 27A of the Securities Act of 1933 and Section 21E of the SecuritiesExchange Act of 1934, as amended, regarding among other things our plans,strategies and prospects -- both business and financial. Although we believethat our plans, intentions and expectations reflected in or suggested by theseforward-looking statements are reasonable, we cannot assure you that we willachieve or realize these plans, intentions or expectations. Forward-lookingstatements are inherently subject to risks, uncertainties and assumptions.Many of the forward-looking statements contained in this news release may beidentified by the use of forward-looking words such as "believe," "expect,""anticipate," "should," "planned," "will," "may," "intend," "estimated," and"potential," among others. Important factors that could cause actual resultsto differ materially from the forward-looking statements we make in this newsrelease include market conditions and those set forth in reports or documentsthat we file from time to time with the United States Securities and ExchangeCommission. All forward-looking statements attributable to MM2 Group, Inc. ora person acting on its behalf are expressly qualified in their entirety bythis cautionary language.

SOURCE MM2 Group, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
U.S. Patent 7,299,083 Awarded to Signalife
S
BLU-MED Announces New Medical Preparedness Contrac...